The FDA has accepted a New Drug Application (NDA) for midomafetamine capsules (MDMA) intended for use in combination with psychological intervention and other supportive services for individuals with PTSD. If approved, this would be the first MDMA-assisted therapy and psychedelic-assisted therapy available. Read more here.

On February 8, 2024, the U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP) held a hearing with CEOs from J&J, Merck, and BMS regarding the high cost of prescription drugs in the U.S. While the CEOs offered policy recommendations to help reduce costs, they could not commit to reducing prices to levels comparable with list prices in other countries. Read more here.